AssetMark Inc
AZN icon

AssetMark Inc’s AstraZeneca AZN Stock Holding History

AssetMark Inc’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.5M Buy
192,721
+1,614
+0.8% +$304K 0.06% 240
2026
Q1 		$37.7M Buy
191,107
+23,413
+14% +$4.51M 0.08% 199
2025
Q4 		$30.8M Buy
167,694
+12,502
+8% +$2.19M 0.06% 242
2025
Q3 		$23.8M Buy
155,192
+9,510
+7% +$1.44M 0.05% 274
2025
Q2 		$20.4M Buy
145,682
+13,550
+10% +$1.9M 0.05% 282
2025
Q1 		$19.4M Buy
132,132
+13,007
+11% +$1.88M 0.05% 249
2024
Q4 		$15.6M Buy
119,125
+5,510
+5% +$771K 0.04% 286
2024
Q3 		$17.7M Buy
113,615
+6,353
+6% +$1.03M 0.05% 247
2024
Q2 		$16.7M Buy
107,262
+9,596
+10% +$1.44M 0.05% 245
2024
Q1 		$13.2M Buy
97,666
+20,213
+26% +$2.68M 0.04% 258
2023
Q4 		$10.4M Buy
77,453
+7,821
+11% +$1.02M 0.04% 263
2023
Q3 		$9.43M Buy
69,632
+4,874
+8% +$666K 0.04% 259
2023
Q2 		$9.27M Buy
64,758
+2,480
+4% +$365K 0.04% 256
2023
Q1 		$8.65M Buy
62,278
+4,524
+8% +$609K 0.04% 255
2022
Q4 		$7.83M Buy
57,754
+10,240
+22% +$1.28M 0.03% 247
2022
Q3 		$5.21M Buy
47,514
+10,519
+28% +$1.33M 0.02% 266
2022
Q2 		$4.89M Buy
36,995
+14,868
+67% +$1.95M 0.02% 262
2022
Q1 		$2.94M Buy
22,127
+11,741
+113% +$1.41M 0.01% 299
2021
Q4 		$1.21M Buy
10,386
+3,969
+62% +$467K 0.01% 382
2021
Q3 		$771K Buy
6,417
+4,182
+187% +$487K ﹤0.01% 410
2021
Q2 		$268K Buy
2,235
+389
+21% +$42.7K ﹤0.01% 545
2021
Q1 		$184K Sell
1,846
-105
-5% -$10.6K ﹤0.01% 565
2020
Q4 		$195K Sell
1,951
-39
-2% -$4.13K ﹤0.01% 546
2020
Q3 		$218K Sell
1,990
-6,186
-76% -$688K ﹤0.01% 510
2020
Q2 		$865K Sell
8,176
-124,055
-94% -$12.8M 0.01% 334
2020
Q1 		$11.8M Sell
132,231
-4,384
-3% -$413K 0.1% 157
2019
Q4 		$13.6M Buy
136,615
+46,320
+51% +$4.36M 0.1% 176
2019
Q3 		$8.05M Buy
90,295
+995
+1% +$86.3K 0.07% 216
2019
Q2 		$7.37M Buy
89,300
+87,114
+3,985% +$6.83M 0.06% 203
2019
Q1 		$177K Sell
2,186
-222
-9% -$17.5K ﹤0.01% 462
2018
Q4 		$183K Sell
2,408
-665
-22% -$51.9K ﹤0.01% 456
2018
Q3 		$243K Sell
3,073
-150
-5% -$11.3K ﹤0.01% 428
2018
Q2 		$226K Sell
3,223
-42
-1% -$3.02K ﹤0.01% 439
2018
Q1 		$228K Sell
3,265
-253
-7% -$17.5K ﹤0.01% 431
2017
Q4 		$244K Sell
3,518
-48,596
-93% -$3.28M ﹤0.01% 448
2017
Q3 		$3.53M Sell
52,114
-52,243
-50% -$3.3M 0.04% 226
2017
Q2 		$7.12M Buy
104,357
+8,653
+9% +$565K 0.09% 167
2017
Q1 		$5.96M Buy
95,704
+41,398
+76% +$2.41M 0.08% 176
2016
Q4 		$2.97M Buy
54,306
+5,148
+10% +$292K 0.04% 202
2016
Q3 		$3.23M Sell
49,158
-5,329
-10% -$348K 0.05% 187
2016
Q2 		$3.29M Buy
54,487
+3,947
+8% +$229K 0.06% 185
2016
Q1 		$2.85M Buy
50,540
+8,030
+19% +$482K 0.05% 189
2015
Q4 		$2.89M Buy
42,510
+13,573
+47% +$890K 0.05% 182
2015
Q3 		$1.84M Buy
28,937
+28,593
+8,312% +$1.88M 0.04% 194
2015
Q2 		$22K Buy
+344
New +$23.6K ﹤0.01% 457

Other funds holding AZN

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
BTCPP
Border to Coast Pensions Partnership Leeds, United Kingdom $6.78B AUM 31.6% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $2.92B AUM
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

AssetMark Inc's AZN Position: Q2 2026 in Review

AssetMark Inc increased its AstraZeneca (AZN) stake by 0.84% in Q2 2026, buying an estimated $304K and bringing the position to 192,721 shares worth $36.5M. The position accounts for 0.06% of the portfolio, ranked #240.

AssetMark Inc first reported a position in AZN in Q2 2015 and has held it in 45 quarters since. The position peaked at $37.7M in Q1 2026. 655 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • AssetMark Inc held 192,721 shares of AstraZeneca worth $36.5M as of Q2 2026.
  • AssetMark Inc bought 1,614 AstraZeneca shares in Q2 2026, an estimated $304K.
  • AstraZeneca made up 0.06% of AssetMark Inc's portfolio in Q2 2026, its #240 holding.
  • AssetMark Inc first reported a position in AstraZeneca in Q2 2015 and has held it in 45 quarters since.
  • AssetMark Inc's AstraZeneca position peaked at $37.7M in Q1 2026.
  • 655 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.